Ameet Mallik is currently President and CEO of ADC Therapeutics, a commercial-stage biotechnology company focused on the lives of those impacted by cancer with its next-generation targeted antibody drug conjugates. Ameet also serves as Board Member and Strategic Advisor to other biotechnology companies.
Prior to this, Ameet served as CEO of Rafael Holdings. Ameet spent 16 years in various leadership roles within Novartis. He held a number of leadership positions at Novartis Oncology including Executive Vice President, Head of U.S., Senior Vice President, Head of Global Marketing, Value and Access, and Senior Vice President, Head of Latin America and Canada. Prior to this, he was Global Head of Biopharmaceuticals & Oncology Injectables at Sandoz, a Novartis company. Ameet began his career at Novartis as Head of Strategic Planning. Prior to Novartis, he worked as an Associate Principal at McKinsey and Company.
He received an M.B.A. from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He also holds an M.S. in Biotechnology and B.S. in Chemical Engineering, both from Northwestern University.